A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Andrew H. Wei(The Royal Melbourne Hospital), Jan Davidson‐Moncada(MacroGenics (United States)), Ezio Bonvini(MacroGenics (United States)), Eileen McNulty(MacroGenics (United States)), Yishai Ofran(Shaare Zedek Medical Center), Jan Baughman(University of California System), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Jacob M. Rowe(Technion – Israel Institute of Technology), Yakir Moshe(Tel Aviv University), María Calbacho(Hospital Universitario 12 De Octubre), Jichao Sun(MacroGenics (United States)), Jaime Pérez de Oteyza(Hospital Universitario HM Sanchinarro), Ofir Wolach(Tel Aviv University), Jordi Sierra Gil(Hospital de Sant Pau), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 15
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k